Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Endocrinology • Vol. 148, Issue 2 • 2007
Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension.
Journal of hypertension • Vol. 25, Issue 3 • 2007
Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).
American journal of nephrology • Vol. 26, Issue 5 • 2006
Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice.
Cardiovascular research • Vol. 69, Issue 1 • 2006
